These data from CARDIO-TTRansform were presented at HFSA 2026, highlighting positive data from the trial despite its failure to improve cardiovascular mortality.
|Podcasts|November 7, 2022
Don't Miss a Beat: AHA 2022
Advertisement
Don’t Miss a Beat is on the road again for their November episode!
This time hosts Muthiah Vaduganathan, MD, MPH, of Brigham and Women’s Hospital, and Stephen Greene, MD, of the Duke University School of Medicine, are bringing you insights from the
All episodes of Don’t Miss a Beat are available in an audio-only format on
Advertisement
Related to this article
A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.
A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.
A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.
A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.
George Washko, MD, discusses a late-breaking OBERON/TITANIA analysis showing tozorakimab reduces segmental mucus plug scores in COPD.
Advanced practice providers described how documentation, specialty pharmacy support, and payer requirements shape biologic selection and timing.
Participants said payer criteria and patient goals often outweigh mechanism when choosing biologics, and that shared decision-making is harder in COPD.
Advertisement
Advertisement
Trending on HCPLive
1
Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1
2
Tezepelumab Meets Co-Primary End Points in Phase 3 CROSSING Trial in EoE
3
Biologic Access in Asthma and COPD: Clinical Forum Perspectives
4
Reaching Comprehensive Disease Control in UC, With Stefan Schreiber, MD
5